NASDAQ:CLLS Cellectis Q3 2025 Earnings Report $1.34 -0.06 (-4.29%) Closing price 04:00 PM EasternExtended Trading$1.34 0.00 (0.00%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cellectis EPS ResultsActual EPS$0.01Consensus EPS -$0.10Beat/MissBeat by +$0.11One Year Ago EPSN/ACellectis Revenue ResultsActual Revenue$37.16 millionExpected Revenue$8.22 millionBeat/MissBeat by +$28.95 millionYoY Revenue GrowthN/ACellectis Announcement DetailsQuarterQ3 2025Date11/7/2025TimeAfter Market ClosesConference Call DateThursday, November 13, 2025Conference Call Time4:30PM ETUpcoming EarningsCellectis' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedulesConference Call ResourcesInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsInterim Report Cellectis Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSOctober 6 at 4:33 PM | globenewswire.comMonthly information on share capital and company voting rightsOctober 6 at 4:30 PM | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 7 at 1:00 AM | The Oxford Club (Ad)Cellectis SA - depositary receipt price target decreased by 53.47% to $3.63October 2, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSOctober 1, 2026 | prnewswire.comCellectis S.A. (NASDAQ:CLLS) Stock Has Average Target Price of $5.46 According to BrokeragesSeptember 30, 2026 | americanbankingnews.comSee More Cellectis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email. Email Address About CellectisCellectis (NASDAQ:CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic cell therapies for the treatment of cancer. The company uses its TALEN gene-editing technology to modify immune cells, including T cells, with the goal of creating “off-the-shelf” therapies that can be manufactured in advance and administered to multiple patients. Cellectis’ development programs include UCART, or Universal Chimeric Antigen Receptor T-cell, therapies designed to target specific cancer antigens. Its research and development activities cover hematologic malignancies and solid tumors, with programs involving engineered T cells and other genetically modified immune-cell products. The company’s approach is intended to improve the scalability and accessibility of cell therapy compared with treatments manufactured individually for each patient. Founded in France in 1999, Cellectis has operations and research activities in Europe and the United States and conducts clinical development internationally. The company was co-founded by André Choulika and David Sourdive; David Sourdive has served as chief executive officer. Cellectis has also pursued strategic collaborations to advance the development and potential commercialization of its gene-edited cell therapies.View Cellectis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
